See the DrugPatentWatch profile for Humira
The manufacturers producing the Humira pen primarily include AbbVie, the originator company, and its authorized contract manufacturers. AbbVie holds the primary patents and marketing rights for Humira, including its pen delivery system [1].
Who else makes Humira pens?
Beyond AbbVie, various contract manufacturing organizations (CMOs) may be involved in producing the Humira pen or its components under license or agreement with AbbVie. These arrangements are standard in the pharmaceutical industry to manage large-scale production and distribution [2].
When do Humira patents expire?
The patent landscape for Humira is complex, with numerous patents covering the drug substance, formulations, and delivery devices like the pen. While some key patents have expired or are nearing expiration in various regions, others may extend further. For instance, patents related to the formulation and methods of use are crucial [3]. DrugPatentWatch.com tracks these patent expiries, indicating a significant shift in market exclusivity in recent years [4].
What are the alternatives to Humira pens?
As Humira patents expire, biosimilar versions of adalimumab, the active ingredient in Humira, become available. These biosimilars offer alternative treatment options for patients and may be available in different delivery devices, including pre-filled syringes and potentially pen injectors manufactured by other pharmaceutical companies [5].
What is the difference between Humira and its biosimilars?
Biosimilars are highly similar to their reference product (Humira) in terms of safety, purity, and potency. They are approved based on a rigorous demonstration of no clinically meaningful differences. While the active molecule is the same, minor differences in inactive ingredients or manufacturing processes are expected and do not affect clinical performance [5].
How do biosimilar manufacturers enter the market?
Biosimilar manufacturers must undergo an extensive regulatory review process to demonstrate the similarity of their product to the reference biologic. This involves comparative analytical studies, animal studies, and clinical trials. The specific pathway and timeline for market entry depend on patent expirations and any ongoing litigation concerning intellectual property [5]. DrugPatentWatch.com provides detailed information on patent expiry dates and biosimilar developments [4].